Merck & Co Inc(MRK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | DJIA, S&P 500 | P/E | 117.92 | EPS (ttm) | 1.25 | Insider Own | 0.1% | Shs Outstand | 2.47B | Perf Week | -1.55% |
| Market Cap | 363.98B | Forward P/E | 15.45 | EPS next Y | 247.67% | Insider Trans | -8.47% | Shs Float | 2.46B | Perf Month | 12.69% |
| Enterprise Value | 410.76B | PEG | 2.84 | EPS next Q | 2.22 | Inst Own | 83.08% | Short Float | 0.99% | Perf Quarter | 23.35% |
| Income | 3.17B | P/S | 5.49 | EPS this Y | -69.42% | Inst Trans | 0.51% | Short Ratio | 2.33 | Perf Half Y | 26% |
| Sales | 66.29B | P/B | 8.69 | EPS next 5Y | 5.45% | ROA | 2.57% | Short Interest | 24.51M | Perf YTD | 40.16% |
| Book/sh | 16.99 | P/C | 50.68 | EPS past 3/5Y | 8.43% 21.23% | ROE | 6.98% | 52W High | -5.98% ($156.92) | Perf Year | 74.36% |
| Cash/sh | 2.91 | P/FCF | 22.66 | Sales past 3/5Y | 3.55% 9.34% | ROIC | 3.41% | 52W Low | 90.16% ($77.58) | Perf 3Y | 35.29% |
| Dividend Est. | $3.41 (2.31%) | EV/EBITDA | 21.6 | EPS Y/Y TTM | -80.62% | Gross Margin | 72.43% | Volatility(W/M) | 2.05% 2.53% | Perf 5Y | 99.85% |
| Dividend TTM | 3.36 | EV/Sales | 6.2 | Sales Y/Y TTM | 4.51% | Oper. Margin | 18.81% | ATR (14) | 3.85 | Perf 10Y | 147.59% |
| Dividend Ex-Date | 2026/9/15 | Quick Ratio | 1.1 | EPS Q/Q | -130.68% | Profit Margin | 4.79% | RSI (14) | 56.86 | Recom | 1.81 |
| Dividend Gr. 3/5Y | 5.42% 5.75% | Current Ratio | 1.32 | Sales Q/Q | 4.94% | SMA20 | 0.52% ($146.77) | Beta | 0.22 | Target Price | $151.76 |
| Payout | 45.05% | Debt/Eq | 1.29 | Earnings | 2026/8/4 | SMA50 | 9% ($135.35) | Rel Volume | 0.74 | Prev Close | $148.46 |
| Employees | 75000 | LT Debt/Eq | 1.22 | EPS/Sales Surpr. | 51.94% 1.45% | SMA200 | 24.05% ($118.93) | Avg Volume(3M) | 10.52M | Price | $147.53 |
| IPO | 1946/6/15 | Option/Short | Yes/Yes | Trades | 58918 | Volume | 7,758,382 | Change | -0.63% |
Company
MRK is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 This major U.S. pharmaceutical company develops Keytruda, an immuno-oncology treatment, along with vaccines and animal health medicines. Founded in the United States in 1891, it is a long-established pharmaceutical leader headquartered in the U.S. and holds leading positions globally in oncology, vaccines, and animal health.
Over the past 1 year, on the higher side
6% below its 1-year high.
Upcoming eventsD-days to next ex-dividend
Ex-dividend September 15
MRK has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -69.4% this year.
Tap to view numbers
The price looks about right
Trading at 117.9 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +35.3% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 2.31% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 83.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PPH 0.10%
FTXH 0.07%
GDOC 0.06%
TRUH 0.06%
XLV 0.06%It ranks #4 in the industry
Based on market cap of $364B.
MRK $364B PER 117.9
LLY $1.1T PER 38.2
JNJ $644B PER 31.0
ABBV $443B PER 70.9
실적분석 · 8/4 Merck ($MRK) Q2 2026 Earnings Analysis — Revenue and Adjusted EPS Both Beat; Full-Year Revenue Guidance Raised 투자 가이드 · 4/11 The Complete 2026 Guide to U.S. Dividend Aristocrats 투자 가이드 · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners See all posts on this stock FAQ
What kind of company is MRK?
MRK belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of MRK?
The market cap of MRK is approximately $364.0B, ranking 38 within its sector.
Does MRK pay dividends?
MRK has a dividend yield of approximately 2.31%, with an annual dividend of $3.41.
What is the P/E ratio of MRK?
MRK has a P/E ratio of approximately 117.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for MRK?
MRK has recorded a 52-week high of $156.92 and a low of $77.58.
